Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
PLoS One
2015 Jan 01;109:e0136659. doi: 10.1371/journal.pone.0136659.
Show Gene links
Show Anatomy links
Clinical Features and Gene Mutations of Lung Cancer Patients 30 Years of Age or Younger.
Wang Y
,
Chen J
,
Ding W
,
Yan B
,
Gao Q
,
Zhou J
.
???displayArticle.abstract???
PURPOSE: Few studies examining the clinical features and gene mutations in lung cancer patients 30 years of age or younger have been published. A trend towards increasing morbidity has been noted in young patients; thus, an urgent need exists to explore this subgroup of patients.
METHODS: Patients aged ≤30 years with pathologically diagnosed lung cancer were retrospectively evaluated. We reviewed the clinical features, gene mutations and prognosis of each patient.
RESULTS: Forty-one patients were included in this study. The mean age was 26.4±3.5 years. Cough, tightness/dyspnea and chest pain were common symptoms, and 58.5% of patients presented with advanced stages of lung cancer. Adenocarcinoma was the predominant histologic type noted in these young patients. Masses and nodules were the dominant imaging features observed upon lung computed tomography (CT). Thoracic lymphadenopathy occurred very frequently in these patients. Five of 6 patients with echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) gene fusions presented solid masses with no ground-glass opacity (GGO) and thoracic multifocal lymphadenopathy. Six of 22 (27.2%) cases contained EML4-ALK gene fusions. In addition, 5 of 22 (22.7%) patients harbored epidermal growth factor receptor (EGFR) mutations, and 2 of 17 patients exhibited KRAS and ROS1 gene mutations. The median survival times were 44.2 months for patients with early stage disease and 8 months for patients with advanced NSCLC disease. The one-year and 5-year survival rates were 56.6% and 38.6%, respectively.
CONCLUSIONS: Increased gene mutation frequencies are noted in these very young lung cancer patients. This finding indicates that the detection of gene mutations in these patients is important and will help to determine the appropriate targeted therapy.
???displayArticle.pubmedLink???
26332764
???displayArticle.pmcLink???PMC4557988 ???displayArticle.link???PLoS One
Fig 1. Thoracic CT findings of representative NSCLC patients with EML4-ALK gene fusions.A, B: mass with no GGO; C: multiple nodules; D: multifocal lymphadenopathy.
Fig 2. Survival curves for lung cancer patients are presented.A: Overall survival curves for 25 NSCLC patients; B: Survival by stage; C: Survival by oncogenic drivers; D: Survival by targeted therapy.
Ak,
Lung cancer in individuals less than 50 years of age.
2007, Pubmed
Ak,
Lung cancer in individuals less than 50 years of age.
2007,
Pubmed
Camidge,
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.
2012,
Pubmed
Cha,
Screening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.
2014,
Pubmed
Doebele,
Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.
2012,
Pubmed
Duan,
Outcome and prognosis for patients younger than thirty with primary lung cancer.
2013,
Pubmed
Fukui,
Clinicoradiologic characteristics of patients with lung adenocarcinoma harboring EML4-ALK fusion oncogene.
2012,
Pubmed
,
Echinobase
Hsu,
Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.
2012,
Pubmed
Hsu,
Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.
2011,
Pubmed
Jiang,
Comparisons of multiple characteristics between young and old lung cancer patients.
2012,
Pubmed
Kim,
Clinicopathologic and molecular characteristics of lung adenocarcinoma arising in young patients.
2012,
Pubmed
Korpanty,
Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS.
2014,
Pubmed
Kozielski,
Lung cancer in patients under the age of 40 years.
2012,
Pubmed
Kuo,
Non-small cell lung cancer in very young and very old patients.
2000,
Pubmed
Lara,
Predictors of survival for younger patients less than 50 years of age with non-small cell lung cancer (NSCLC): a California Cancer Registry analysis.
2014,
Pubmed
Liam,
Lung cancer in patients younger than 40 years in a multiracial Asian country.
2000,
Pubmed
Marugame,
Trends in lung cancer mortality among young adults in Japan.
2005,
Pubmed
Mauri,
Non-small cell lung cancer in the young: a retrospective analysis of diagnosis, management and outcome data.
2006,
Pubmed
McDuffie,
Female-male differences in patients with primary lung cancer.
1987,
Pubmed
Mizushima,
Lung carcinoma in patients age younger than 30 years.
1999,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Nagashima,
High prevalence of gene abnormalities in young patients with lung cancer.
2013,
Pubmed
Nugent,
Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment.
1997,
Pubmed
Pan,
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.
2014,
Pubmed
Pao,
New driver mutations in non-small-cell lung cancer.
2011,
Pubmed
Park,
Anaplastic lymphoma kinase gene rearrangements in patients with advanced-stage non-small-cell lung cancer: CT characteristics and response to chemotherapy.
2014,
Pubmed
Rosell,
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
2012,
Pubmed
Sharma,
Epidermal growth factor receptor mutations in lung cancer.
2007,
Pubmed
Shaw,
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
2013,
Pubmed
She,
Lung cancer in China: challenges and interventions.
2013,
Pubmed
Shigematsu,
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.
2005,
Pubmed
Sholl,
Biomarkers in lung adenocarcinoma: a decade of progress.
2015,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Strand,
Adolescent smoking and trends in lung cancer incidence among young adults in Norway 1954-1998.
2004,
Pubmed
Subramanian,
Distinctive characteristics of non-small cell lung cancer (NSCLC) in the young: a surveillance, epidemiology, and end results (SEER) analysis.
2010,
Pubmed
Takeuchi,
RET, ROS1 and ALK fusions in lung cancer.
2012,
Pubmed
Tian,
Surgery for young patients with lung cancer.
2003,
Pubmed
Togashi,
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
2011,
Pubmed
Torre,
Global cancer statistics, 2012.
2015,
Pubmed
VandenBussche,
Molecular alterations in non-small cell lung carcinomas of the young.
2014,
Pubmed
Whooley,
Bronchogenic carcinoma in patients age 30 and younger.
2000,
Pubmed
Yang,
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.
2015,
Pubmed
Ye,
Analysis of the molecular and clinicopathologic features of surgically resected lung adenocarcinoma in patients under 40 years old.
2014,
Pubmed
Zhang,
Multicenter analysis of lung cancer patients younger than 45 years in Shanghai.
2010,
Pubmed
Zhao,
Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples.
2014,
Pubmed
Zhou,
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
2011,
Pubmed
Zhou,
Accurate and economical detection of ALK positive lung adenocarcinoma with semiquantitative immunohistochemical screening.
2014,
Pubmed